A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression
Phase of Trial: Phase III
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Esketamine (Primary) ; Duloxetine; Escitalopram; Sertraline; Venlafaxine
- Indications Depression; Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms TRANSFORM-3
- Sponsors Janssen Research & Development
- 26 Sep 2017 Status changed from recruiting to completed.
- 30 Jun 2017 Planned End Date changed from 26 Jun 2018 to 26 Mar 2021.
- 08 May 2017 Planned End Date changed from 18 May 2021 to 26 Jun 2018.